Recent findings from McKinsey reveal that generative AI (GenAI) in the medical instruments industry has transitioned from experimental to operational, with roughly 50% of US healthcare leaders implementing it in their organizations and more than 80% deploying initial use cases. The global AI healthcare market is projected to grow at a CAGR of 38.9%, reaching a valuation of $36.67 billion by 2025, emphasizing the accelerating adoption of AI technologies in drug development and diagnostics.
In regulatory updates, the EU AI Act 2024 mandates stringent requirements for high-risk AI systems, while the FDA’s AI/ML-Enabled Medical Devices list has grown to over 1,400 devices by the end of 2025, highlighting the substantial regulatory framework in place. The Zacks Medical Instruments industry currently holds a Zacks Industry Rank of #139, indicating it is underperforming in comparison to the broader S&P 500, with a 6.9% decline over the past year.
The increasing trend of mergers and acquisitions in the sector was demonstrated by notable transactions, including Abbott’s $23 billion acquisition of Exact Sciences and Blackstone’s $18 billion deal for Hologic. This ongoing consolidation indicates a robust strategy among companies to enhance market positioning amidst growing competition and technological advancements.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
